Abstract
Objective
The nitric-oxide pathway plays a crucial role in the pathogeneses of asthma and NOS3-encoded endothelial nitric oxide synthase is one of the main components of the pathway. Variants of NOS3 are known to contribute to asthma development and pathophysiology.
Methods
We investigated the association of NOS3-c.894G/T (rs1799983) with asthma risk and severity by studying frequencies of its genotypes and alleles in 555 asthmatics (93 intermittent, 240 mild, 158 moderate, and 64 severe asthma cases) and 351 control participants using the PCR-FRLP method, logistic regression analysis and generalized ordered logit estimates.
Results
GT genotype (ORadj: 1.39; CI: 1.04–1.85; p = 0.026), dominant model GT + TT (ORadj: 1.41; CI: 1.07–1.87; p = 0.015), and T allele (ORadj: 1.32; CI: 1.05–1.67; p = 0.018) was associated with increased ORs in asthmatics. Also, the frequency of GT + TT (ORadj: 1.55; CI: 1.01–2.38; p = 0.044) was significantly higher in males. Furthermore, GT genotype (ORadj: 1.39; CI: 1.04–1.85; p = 0.024), GT + TT (ORadj: 1.42; CI: 1.07–1.87; p = 0.014), and T allele (ORadj: 1.32; CI: 1.05–1.66; p = 0.018) in total population and GT + TT (ORadj: 1.56; CI: 1.02–2.37; p = 0.04) in males were significantly associated with increased risk of severe, moderate, mild, intermittent asthma vs. controls. Also, GT genotype (ORadj: 1.39; CI: 1.02–1.91; p = 0.039) was significantly more frequent in severe, moderate grades vs. lower severity grades in the total population. Frequencies of GT genotype (ORadj: 1.77; CI: 1.05–3.00; p = 0.032) and GT + TT (ORadj: 1.74; CI: 1.04–2.90; p = 0.036) in total population and GT genotype (ORadj: 2.40; CI: 1.16–4.97; p = 0.018) and GT + TT (ORadj: 2.30; CI: 1.12–4.74; p = 0.023) in male subpopulation were significantly higher in severe cases compared to lower grades.
Conclusions
NOS3-c.894G/T may be associated with asthma risk and its severer grades, with greater effects in men.
Availability of data and materials
All data are available upon formal asking from the corresponding author.
Consent to participate
All participants signed informed consent for participation and the use of data in research.
Disclosure statement
The authors have no competing interests to declare.
Ethics approval
Research protocols were approved by the medical ethics committee of the research council of the National Institute for Medical Research Development, Tehran, Iran (IR-NIMAD-REC-1396-032).